What EBITDA multiple do healthcare companies sell for?

In Bankerly's database of sourced transactions, lower-middle-market healthcare companies (targets at or below $25M of EBITDA) sold for a median of 8.8× trailing EBITDA, with the middle half of deals between 6.1× and 11.5×, across 24 transactions (data as of October 2026). Disclosed deals skew larger than a typical owner-run company.

What revenue multiple do healthcare companies sell for?

The median EV/Revenue multiple in the same sample is 1.5×, with the middle half between 1.1× and 2.6× across 21 transactions. Buyers of profitable companies usually price on EBITDA; revenue multiples matter most for fast-growing or not-yet-profitable businesses.

Why might my company sell below these medians?

Smaller companies, owner dependence, customer concentration, thin or volatile margins and weak financial records all pull a multiple down. Disclosed transactions are skewed toward larger, better-documented companies, so the quartile range matters more than any single number.

M&A multiples by industry

Healthcare M&A valuation multiples

Lower-middle-market healthcare companies have sold for a median 8.8× trailing EBITDA. The middle half of the 24 sourced transactions fall between 6.1× and 11.5×; data as of October 2026.

Median EV/EBITDA: 8.8×
Middle half: 6.1× – 11.5×
Median EV/Revenue: 1.5×
Transactions: 24

Quartiles

Measure	p25 – median – p75	n
EV/EBITDA	6.1× – 8.8× – 11.5×	24
EV/Revenue	1.1× – 1.5× – 2.6×	21

Trailing multiples of enterprise value, targets at or below $25M of EBITDA, sourced transactions only, deals from 2012–2026. The database tracks 241 sourced healthcare transactions at every size; only those that disclose a multiple and fall in the band are counted here. Figures from fewer than 8 transactions are withheld.

By niche

Peer groups inside the sector with enough disclosed deals to publish. A niche can overlap the sector’s other groups.

Niche	EV/EBITDA p25 – median – p75	n
Medical devices and diagnostics	4.5× – 8.5× – 9.0×	9

By company size

Smaller companies usually trade at lower multiples. Where both halves of the band have enough deals, they are shown separately. Why multiples differ by size.

Size band	EV/EBITDA p25 – median – p75	n
Targets with EBITDA up to $5M	4.5× – 6.9× – 9.5×	12
Targets with EBITDA of $5M to $25M	8.8× – 9.9× – 12.2×	12

Recent transactions in the sample

The most recent disclosed deals behind the figures above, each linked to its source.

Target	Acquirer	Year	EV/EBITDA
Welch Fluorocarbon, Inc.	UFP Technologies, Inc.	2024	11.5×
Marble Medical, Inc.	UFP Technologies, Inc.	2024	4.5×
AJR Enterprises, LLC	UFP Technologies, Inc.	2024	6.0×
Pulse Technologies, Inc.	Integer Holdings Corporation	2024	12.7×
Viewgol, LLC	CPSI (TruBridge, Inc.)	2023	8.0×
DAS Medical Holdings, LLC	UFP Technologies, Inc. (NASDAQ: UFPT)	2021	8.5×
VRI (VRI Intermediate Holdings, LLC)	ModivCare Inc.	2021	15.0×
Irving Burton Associates, LLC (IBA)	DLH Holdings Corp.	2020	7.8×
MedPartners HIM	AMN Healthcare Services, Inc.	2018	9.8×

Estimate a healthcare company’s value

The calculator applies these multiples, narrowed to deals near the size you enter, to your revenue and EBITDA. Free, no sign-up.

This valuation guidance is an educational estimate generated from publicly sourced comparable-transaction data and standard methodologies. It is not an appraisal, a fairness opinion, or investment, legal, or tax advice, and it does not predict the price any buyer will pay. Actual outcomes depend on diligence, market conditions, and negotiation. Consult your own advisors before making decisions.

Selling a healthcare company

Citing a figure?

This page updates as deals are added. The fixed 2026-Q4 snapshot recorded a median of 8.9× for Healthcare (n=26) and will not change. Cite the 2026-Q4 snapshot.

Other industries

How these figures are built: methodology.